531 related articles for article (PubMed ID: 16430719)
1. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
[TBL] [Abstract][Full Text] [Related]
3. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Romagnani P; Grosso M; Ferrannini E; Serio M
Eur J Endocrinol; 2006 May; 154(5):651-8. PubMed ID: 16645011
[TBL] [Abstract][Full Text] [Related]
4. Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy.
Antonelli A; Ferrari SM; Corrado A; Ferrannini E; Fallahi P
Thyroid; 2013 Nov; 23(11):1461-9. PubMed ID: 23721189
[TBL] [Abstract][Full Text] [Related]
5. Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves' disease.
Leite AC; Pedro AB; Romaldini JH
Horm Metab Res; 2011 Mar; 43(3):194-9. PubMed ID: 21283953
[TBL] [Abstract][Full Text] [Related]
6. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.
Antonelli A; Rotondi M; Fallahi P; Grosso M; Boni G; Ferrari SM; Romagnani P; Serio M; Mariani G; Ferrannini E
J Clin Endocrinol Metab; 2007 Apr; 92(4):1485-90. PubMed ID: 17244787
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum IL-16 and RANTES levels in patients with autoimmune thyroid diseases and modulation by methimazole therapy.
Gu X; Zheng L; Chen X; Ruan L; Zhang H; Ge S; Zhu H; Lin X; Shen F
Horm Metab Res; 2012 Jun; 44(6):482-7. PubMed ID: 22473756
[TBL] [Abstract][Full Text] [Related]
8. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
[TBL] [Abstract][Full Text] [Related]
9. Thyroid hormone modulates insulin-like growth factor-I(IGF-I) and IGF-binding protein-3, without mediation by growth hormone, in patients with autoimmune thyroid diseases.
Inukai T; Takanashi K; Takebayashi K; Fujiwara Y; Tayama K; Takemura Y
Horm Metab Res; 1999 Oct; 31(10):576-9. PubMed ID: 10596968
[TBL] [Abstract][Full Text] [Related]
10. Increased serum neopterin levels in patients with Graves' disease.
Wagner R; Hayatghebi S; Rosenkranz M; Reinwein D
Exp Clin Endocrinol; 1993; 101(4):249-54. PubMed ID: 8307114
[TBL] [Abstract][Full Text] [Related]
11. Thyrotropin binding inhibiting immunoglobulins (TBII) in Graves' disease, toxic nodular goitre and autoimmune thyroiditis.
Wägar G; Mäkinen T; Lamberg BA; Gordin A; Apter L; Pekonen F
Ann Clin Res; 1982 Apr; 14(2):83-9. PubMed ID: 6184007
[TBL] [Abstract][Full Text] [Related]
12. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
13. Expression of Bcl-2 family proteins in thyrocytes from young patients with immune and nonimmune thyroid diseases.
Bossowski A; Czarnocka B; Bardadin K; Urban M; Niedziela M; Dadan J
Horm Res; 2008; 70(3):155-64. PubMed ID: 18663316
[TBL] [Abstract][Full Text] [Related]
14. Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2).
Phenekos C; Vryonidou A; Gritzapis AD; Baxevanis CN; Goula M; Papamichail M
Neuroimmunomodulation; 2004; 11(4):209-13. PubMed ID: 15249726
[TBL] [Abstract][Full Text] [Related]
15. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
[TBL] [Abstract][Full Text] [Related]
16. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
[TBL] [Abstract][Full Text] [Related]
18. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter.
Gedik O; Ozdemir T; Akalin S
Isr J Med Sci; 1991 Jul; 27(7):361-4. PubMed ID: 1712765
[TBL] [Abstract][Full Text] [Related]
19. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
Bossowski A; Stasiak-Barmuta A; Urban M
Horm Res; 2005; 64(4):189-97. PubMed ID: 16220002
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Antonelli A; Rotondi M; Ferrari SM; Fallahi P; Romagnani P; Franceschini SS; Serio M; Ferrannini E
J Clin Endocrinol Metab; 2006 Feb; 91(2):614-20. PubMed ID: 16303841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
